Bioremediation Kinetics of Pharmaceutical Industrial Effluent

In recent years, concerns about the occurrence and fate of pharmaceuticals that could be present in water and wastewater has gained increasing attention. With the public’s enhanced awareness of eco-safety, environmentally benign methods based on microorganisms have become more accepted methods of re...

Full description

Bibliographic Details
Main Authors: M. Šabić, M. Vuković Domanovac, Z. Findrik Blažević, E. Meštrović
Format: Article
Language:English
Published: Croatian Society of Chemical Engineers 2015-05-01
Series:Kemija u Industriji
Subjects:
Online Access:http://pierre.fkit.hr/hdki/kui/vol64/broj5-6/229.pdf
id doaj-7ad9a7aae3a24173b39d5cef52c3c671
record_format Article
spelling doaj-7ad9a7aae3a24173b39d5cef52c3c6712020-11-25T01:08:50ZengCroatian Society of Chemical EngineersKemija u Industriji0022-98301334-90902015-05-01645-622923610.15255/KUI.2014.014Bioremediation Kinetics of Pharmaceutical Industrial EffluentM. Šabić0M. Vuković Domanovac1Z. Findrik Blažević2E. Meštrović3University of Zagreb Faculty of Chemical Engineering and Technology, Zagreb, Croatia University of Zagreb Faculty of Chemical Engineering and Technology, Zagreb, Croatia University of Zagreb Faculty of Chemical Engineering and Technology, Zagreb, Croatia Pliva Hrvatska d.o.o., Zagreb, Croatia In recent years, concerns about the occurrence and fate of pharmaceuticals that could be present in water and wastewater has gained increasing attention. With the public’s enhanced awareness of eco-safety, environmentally benign methods based on microorganisms have become more accepted methods of removing pollutants from aquatic systems. This study investigates bioremediation of pharmaceutical wastewater from pharmaceutical company Pliva Hrvatska d.o.o., using activated sludge and bioaugmented activated sludge with isolated mixed bacterial culture. The experiments were conducted in a batch reactor in submerged conditions, at initial concentration of organic matter in pharmaceutical wastewater, expressed as COD, 5.01 g dm–3 and different initial concentrations of activated sludge, which ranged from 1.16 to 3.54 g dm–3. During the experiments, the COD, pH, concentrations of dissolved oxygen and biomass were monitored. Microscopic analyses were performed to monitor the quality of activated sludge. Before starting with the bioremediation in the batch reactor, toxicity of the pharmaceutical wastewater was determined by toxicity test using bacteria Vibrio fischeri. The obtained results showed that the effective concentration of the pharmaceutical wastewater was EC50 = 17 % and toxicity impact index was TII50 = 5.9, meaning that the untreated pharmaceutical industrial effluent must not be discharged into the environment before treatment. The results of the pharmaceutical wastewater bioremediation process in the batch reactor are presented in Table 1. The ratio γXv ⁄ γX maintained high values throughout all experiments and ranged from 0.90 and 0.95, suggesting that the concentrations of biomass remained unchanged during the experiments. The important kinetic parameters required for performance of the biological removal process, namely μmax, Ks, Ki, Y and kd were calculated from batch experiments (Table 2). Figs. 1 and 2 show the experimental results of changes in concentrations of substrate γS0 = 5.01 g dm<sup>–3</sup> for different initial concentrations of activated sludge in comparison to Endo-Haldane model. Changes in concentrations of activated sludge during four days of experiments P1 and P2 are presented in Figs. 4 and 5, respectively. These results suggest that the bioremediation process is well described by the selected model. Process efficiency of pharmaceutical wastewater treatment was approximately 64.8 % (Fig. 3), while in experiment P2 with bioaugmented activated sludge (Fig. 2), the same efficiency was obtained 24 hours earlier than in experiment P1 (Fig.1). Microscopic examination of the activated sludge (Fig. 6) showed that bioaugmentation has no effect on formation of the flocs, but increases efficiency of the bioremediation in a way that the pharmaceutical wastewater treatment is faster and more efficient with bioaugmented activated sludge (Table 3, Fig. 2).http://pierre.fkit.hr/hdki/kui/vol64/broj5-6/229.pdfpharmaceuticalsKinetics;bioremediation;bioaugmentation;wastewaterpharmaceuticals
collection DOAJ
language English
format Article
sources DOAJ
author M. Šabić
M. Vuković Domanovac
Z. Findrik Blažević
E. Meštrović
spellingShingle M. Šabić
M. Vuković Domanovac
Z. Findrik Blažević
E. Meštrović
Bioremediation Kinetics of Pharmaceutical Industrial Effluent
Kemija u Industriji
pharmaceuticals
Kinetics;
bioremediation;
bioaugmentation;
wastewater
pharmaceuticals
author_facet M. Šabić
M. Vuković Domanovac
Z. Findrik Blažević
E. Meštrović
author_sort M. Šabić
title Bioremediation Kinetics of Pharmaceutical Industrial Effluent
title_short Bioremediation Kinetics of Pharmaceutical Industrial Effluent
title_full Bioremediation Kinetics of Pharmaceutical Industrial Effluent
title_fullStr Bioremediation Kinetics of Pharmaceutical Industrial Effluent
title_full_unstemmed Bioremediation Kinetics of Pharmaceutical Industrial Effluent
title_sort bioremediation kinetics of pharmaceutical industrial effluent
publisher Croatian Society of Chemical Engineers
series Kemija u Industriji
issn 0022-9830
1334-9090
publishDate 2015-05-01
description In recent years, concerns about the occurrence and fate of pharmaceuticals that could be present in water and wastewater has gained increasing attention. With the public’s enhanced awareness of eco-safety, environmentally benign methods based on microorganisms have become more accepted methods of removing pollutants from aquatic systems. This study investigates bioremediation of pharmaceutical wastewater from pharmaceutical company Pliva Hrvatska d.o.o., using activated sludge and bioaugmented activated sludge with isolated mixed bacterial culture. The experiments were conducted in a batch reactor in submerged conditions, at initial concentration of organic matter in pharmaceutical wastewater, expressed as COD, 5.01 g dm–3 and different initial concentrations of activated sludge, which ranged from 1.16 to 3.54 g dm–3. During the experiments, the COD, pH, concentrations of dissolved oxygen and biomass were monitored. Microscopic analyses were performed to monitor the quality of activated sludge. Before starting with the bioremediation in the batch reactor, toxicity of the pharmaceutical wastewater was determined by toxicity test using bacteria Vibrio fischeri. The obtained results showed that the effective concentration of the pharmaceutical wastewater was EC50 = 17 % and toxicity impact index was TII50 = 5.9, meaning that the untreated pharmaceutical industrial effluent must not be discharged into the environment before treatment. The results of the pharmaceutical wastewater bioremediation process in the batch reactor are presented in Table 1. The ratio γXv ⁄ γX maintained high values throughout all experiments and ranged from 0.90 and 0.95, suggesting that the concentrations of biomass remained unchanged during the experiments. The important kinetic parameters required for performance of the biological removal process, namely μmax, Ks, Ki, Y and kd were calculated from batch experiments (Table 2). Figs. 1 and 2 show the experimental results of changes in concentrations of substrate γS0 = 5.01 g dm<sup>–3</sup> for different initial concentrations of activated sludge in comparison to Endo-Haldane model. Changes in concentrations of activated sludge during four days of experiments P1 and P2 are presented in Figs. 4 and 5, respectively. These results suggest that the bioremediation process is well described by the selected model. Process efficiency of pharmaceutical wastewater treatment was approximately 64.8 % (Fig. 3), while in experiment P2 with bioaugmented activated sludge (Fig. 2), the same efficiency was obtained 24 hours earlier than in experiment P1 (Fig.1). Microscopic examination of the activated sludge (Fig. 6) showed that bioaugmentation has no effect on formation of the flocs, but increases efficiency of the bioremediation in a way that the pharmaceutical wastewater treatment is faster and more efficient with bioaugmented activated sludge (Table 3, Fig. 2).
topic pharmaceuticals
Kinetics;
bioremediation;
bioaugmentation;
wastewater
pharmaceuticals
url http://pierre.fkit.hr/hdki/kui/vol64/broj5-6/229.pdf
work_keys_str_mv AT msabic bioremediationkineticsofpharmaceuticalindustrialeffluent
AT mvukovicdomanovac bioremediationkineticsofpharmaceuticalindustrialeffluent
AT zfindrikblazevic bioremediationkineticsofpharmaceuticalindustrialeffluent
AT emestrovic bioremediationkineticsofpharmaceuticalindustrialeffluent
_version_ 1725181460569128960